The stock of Synaptogenix Inc (SNPX) has gone up by 8.98% for the week, with a -2.08% drop in the past month and a -13.06% drop in the past quarter. The volatility ratio for the week is 6.60%, and the volatility levels for the past 30 days are 7.03% for SNPX. The simple moving average for the past 20 days is 8.57% for SNPX’s stock, with a -19.99% simple moving average for the past 200 days.
Is It Worth Investing in Synaptogenix Inc (NASDAQ: SNPX) Right Now?
The stock has a 36-month beta value of 1.46. Opinions on the stock are mixed, with 1 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for SNPX is 1.29M, and at present, short sellers hold a 0.81% of that float. On September 03, 2024, the average trading volume of SNPX was 31.76K shares.
SNPX) stock’s latest price update
Synaptogenix Inc (NASDAQ: SNPX) has experienced a rise in its stock price by 12.07 compared to its previous closing price of 3.53. However, the company has seen a gain of 8.98% in its stock price over the last five trading days. prnewswire.com reported 2024-07-18 that Company holds exclusive rights to family of polyunsaturated fatty acid (PUFA) analogs New patent covers proprietary analogs in the treatment of neurodegenerative diseases NEW YORK, July 18, 2024 /PRNewswire/ — Synaptogenix, Inc. (Nasdaq: SNPX) (“Synaptogenix” or the “Company”), an emerging biopharmaceutical company developing therapeutics for neurodegenerative disorders, today announced a new collaboration agreement with LSU Health New Orleans’ Neuroscience Center of Excellence for pre-clinical testing of the Company’s polyunsaturated fatty acid (PUFA) analogs as a treatment for spinal cord injury (SCI). The Company also announced that the US Patent and Trademark Office (USPTO) recently issued US Patent No.
SNPX Trading at -1.08% from the 50-Day Moving Average
After a stumble in the market that brought SNPX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -70.64% of loss for the given period.
Volatility was left at 7.03%, however, over the last 30 days, the volatility rate increased by 6.60%, as shares surge +4.93% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -6.92% lower at present.
During the last 5 trading sessions, SNPX rose by +8.98%, which changed the moving average for the period of 200-days by -36.68% in comparison to the 20-day moving average, which settled at $3.65. In addition, Synaptogenix Inc saw -41.80% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for SNPX
Current profitability levels for the company are sitting at:
- -600.36 for the present operating margin
- 0.45 for the gross margin
The net margin for Synaptogenix Inc stands at -166.71. The total capital return value is set at -0.32. Equity return is now at value -7.85, with -5.54 for asset returns.
Currently, EBITDA for the company is -8.31 million with net debt to EBITDA at 2.95. When we switch over and look at the enterprise to sales, we see a ratio of -1924.97. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.98.
Conclusion
To sum up, Synaptogenix Inc (SNPX) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
